<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03159845</url>
  </required_header>
  <id_info>
    <org_study_id>Hematology AOUPisa</org_study_id>
    <nct_id>NCT03159845</nct_id>
  </id_info>
  <brief_title>Zinc as Enhancer in Immune Recovery After Stem Cell Transplantation for Hematological Malignancies</brief_title>
  <acronym>ZENITH</acronym>
  <official_title>A Mono-centric, No-profit, Case-control Study With Daily Oral Supplementation of Zinc Sulphate After Autologous Stem Cell Transplantation in Patients Affected by Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Ospedaliero, Universitaria Pisana</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Azienda Ospedaliero, Universitaria Pisana</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients affected by multiple myeloma undergone autologous stem cell transplantation (SCT)
      are enrolled at the moment of stem cell collection. They are randomized 1:1 in two groups at
      the moment of the graft. Patients of the Control group take only standard antimicrobial
      prophylaxis after SCT; the Sample group takes in addition a daily oral supplementation of
      Zinc Sulfate (600 mg/die) from day +5 until day +100 after SCT. Laboratory tests are
      performed on peripheral blood samples.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients affected by multiple myeloma undergone autologous stem cell transplantation (SCT)
      are enrolled at the moment of stem cell collection. They are randomized 1:1 in two groups at
      the moment of the graft. Patients of the Control group take only standard antimicrobial
      prophylaxis after SCT; the Sample group takes in addition a daily oral supplementation of
      Zinc Sulfate (600 mg/die) from day +5 until day +100 after SCT. The aim of the study is to
      investigate the immune reconstitution in presence of Zinc, focused on thymic reconstitution.
      Laboratory tests are performed on peripheral blood samples, collected at 4 time-points: two
      before transplant (at the moment of the enrollment and the day before conditioning) and two
      after transplant (day +30 and +100).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2014</start_date>
  <completion_date type="Anticipated">January 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Case-control study, open, without placebo</intervention_model_description>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Thymic output improvement by TRECs</measure>
    <time_frame>increase of TRECs levels from day +30 until day +100 after transplant</time_frame>
    <description>Measure of T cell receptor excision circles levels on peripheral lymphocytes (TRECs), calculated as number of copies of TRECs/mcLin droplet digital PCR</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Thymic output improvement by flow cytometry</measure>
    <time_frame>days +30, +100 after transplant</time_frame>
    <description>Measure of circulating T naive lymphocytes by 8-colour flow-cytometry. T naive are identified as CD4+/CD8+ lymphocytes with the coexpression of CD45RA, CD27, CD28. The value is estimated as number of T naive/mcL</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Variations in circulating lymphocyte populations</measure>
    <time_frame>days +30, +100 after transplant</time_frame>
    <description>Flow cytometry to determine the variations of t cell subpopulations after graft</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune competence</measure>
    <time_frame>days +30, +100 after transplant</time_frame>
    <description>quantitative polymerase chain reaction on peripheral blood aiming to quantify Torquetenovirus viral load</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]</measure>
    <time_frame>days +30, +100 after transplant</time_frame>
    <description>case report form to report side effects</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Stem Cell Transplant Complications</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients undergone autologous stem cell transplantation. They take levofloxacin 500 mg/d, aciclovir 400 mg bid, fluconazole 200 mg bid from day +10 until day +30 after stem cell transplantation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Zinc</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients undergone autologous stem cell transplantation. They take the same antimicrobial prophylaxis of patients of the Control group, and, in addition, a daily oral supplementation of Zinc Sulfate, 600 mg/die, uncoated tabs, from day +5 until day +100 after transplant</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zinc Sulfate Oral Product</intervention_name>
    <arm_group_label>Zinc</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levofloxacin 500Mg Oral Tablet</intervention_name>
    <description>once daily from day +10 until day +30 after stem cell transplantation</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Zinc</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluconazole 200mg tab</intervention_name>
    <description>twice daily from day +10 until day +30 after stem cell transplantation</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Zinc</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acyclovir 400 MG</intervention_name>
    <description>twice daily from day +10 until day +30 after stem cell transplantation</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Zinc</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  eligibility to stem cell transplantation

        Exclusion Criteria:

          -  allergy to Zinc

          -  copper deficiency or Wilson's syndrome

          -  patients who admit zinc assumption in other drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lorenzo Iovino, MD</last_name>
    <phone>0039 329 2959114</phone>
    <email>iovino-lorenzo@tiscali.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hematology UO</name>
      <address>
        <city>Pisa</city>
        <zip>56126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lorenzo Iovino, MD</last_name>
      <phone>0039 3292959114</phone>
      <email>iovino-lorenzo@tiscali.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 15, 2017</study_first_submitted>
  <study_first_submitted_qc>May 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 19, 2017</study_first_posted>
  <last_update_submitted>June 9, 2017</last_update_submitted>
  <last_update_submitted_qc>June 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Azienda Ospedaliero, Universitaria Pisana</investigator_affiliation>
    <investigator_full_name>Lorenzo Iovino</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>zinc</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zinc</mesh_term>
    <mesh_term>Levofloxacin</mesh_term>
    <mesh_term>Ofloxacin</mesh_term>
    <mesh_term>Fluconazole</mesh_term>
    <mesh_term>Acyclovir</mesh_term>
    <mesh_term>Zinc Sulfate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

